Condyloma Acuminata
📧 Sign up to get email alerts when something new happens for Condyloma Acuminata.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)
This is a clinical trial update for CONDYPSO. It investigates whether anti-psoriatic biologics affect the risk of anogenital warts (condylom…
-
CLINICAL_TRIALS research · 2025-07-22Clinical Trial Update: An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old [Phase 3]
A Phase 3 immuno-bridging study of a nonavalent HPV vaccine expressed in E. coli is comparing immune responses between healthy participants …
-
CLINICAL_TRIALS trial_result · 2025-02-19Clinical Trial Update: Interleukin 4 and Interferon Gamma Predictors of Human Papillomavirus Immunotherapy in Warts
A completed clinical trial exploring whether interleukin-4 and interferon-gamma biomarkers predict responses to HPV immunotherapy in patient…
-
FDA approval · 2023-11-22FDA Approved: PODOFILOX — Original Application (Padagis US LLC)
FDA approved Padagis US LLC's Podofilox (podofilox) topical solution from an original ANDA for treating external genital warts caused by HPV…
-
CLINICAL_TRIALS trial_result · 2020-02-05Clinical Trial Update: Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs) [Phase 2]
Phase 2 trial results summarize efficacy and safety of SR-T100 Gel for external genital warts due to Condyloma Acuminata.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-09-06Clinical Trial Update: Safety and Tolerability Study of V501 in Japanese Boys (V501-200) [Phase 3]
Phase 3 safety and tolerability trial of V501 in Japanese boys with anogenital HPV infection (condyloma acuminata) completed; results posted…
-
CLINICAL_TRIALS trial_result · 2018-08-31Clinical Trial Update: Efficacy and Tolerability Study of V501 in Japanese Males (V501-122) [Phase 3]
Phase 3 trial assessing efficacy and tolerability of V501 in Japanese males with anogenital HPV infection and condyloma acuminata; trial com…
-
FDA approval · 2016-07-08FDA Approved: VEREGEN — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Veregen (sinecatechins) submitted by ANI Pharmaceuticals, Inc., indicating approval of the r…
-
FDA approval · 2013-05-09FDA Approved: VEREGEN — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approved a supplemental application for Veregen (sinecatechins) submitted by ANI Pharmaceuticals, Inc. The action relates to the already…
-
FDA approval · 2012-11-19FDA Approved: VEREGEN — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Veregen (sinecatechins) submitted by ANI Pharmaceuticals, Inc., effectively updating/expandi…
-
CLINICAL_TRIALS trial_result · 2012-05-08Clinical Trial Update: Glizigen-Viudid-External Anogenital Warts in Children and Adolescents [Phase 3]
A Phase 3 trial of Glizigen-Viudid for external anogenital warts in children and adolescents has completed.
-
FDA label_change · 2011-07-15FDA Approved: ZYCLARA — Supplemental Application (Bausch Health US, LLC)
FDA records a supplemental application for ZYCLARA (imiquimod) from Bausch Health US, LLC, filed to update the product labeling.
-
FDA approval · 2008-02-13FDA Approved: VEREGEN — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approved a supplemental application for Veregen (sinecatechins) submitted by ANI Pharmaceuticals, Inc. The supplemental action relates t…
-
FDA approval · 2007-12-19FDA Approved: VEREGEN — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for VEREGEN (sinecatechins) filed by ANI Pharmaceuticals, Inc.
-
FDA approval · 2007-06-27FDA Approved: VEREGEN — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Veregen (sinecatechin) submitted by ANI Pharmaceuticals.